Difference between revisions of "Neuroendocrine carcinoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "=Guidelines=" to "=Guidelines= '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''") |
||
| Line 12: | Line 12: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf NCCN Guidelines - Neuroendocrine and Adrenal Tumors]''. | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf NCCN Guidelines - Neuroendocrine and Adrenal Tumors]''. | ||
Revision as of 19:03, 17 October 2023
| Section editor | |
|---|---|
| Unfilled If you are interested in this role, please contact us at [email protected]. | |
2 regimens on this page
2 variants on this page
|
Note: these are regimens tested in histology-specific populations, please see the main NET page for other regimens.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Neuroendocrine and Adrenal Tumors.
Advanced disease, all lines of therapy
Cisplatin & Etoposide (EP)
EP: Etoposide and Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | IP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
21-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795
Cisplatin & Irinotecan (IC)
IP: Irinotecan, Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | EP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Irinotecan (Camptosar) 60 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795